
Join to view full profile
800 W Magnolia AveFort Worth, TX 76104
Phone+1 817-759-7000
Dr. Xiong is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1995 - 1998
Shanghai Medical UniversityClass of 1984
Certifications & Licensure
TX State Medical License 1999 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013-2015
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2014
Clinical Trials
Publications & Presentations
PubMed
- 55 citationsPhase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)Herbert Hurwitz, Benjamin R. Tan, James A. Reeves, Henry Xiong, Brad Somer
The Oncologist. 2019-07-01 - 1 citationsTwo phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.Kamalesh Kumar Sankhala, Chris H. Takimoto, Alain C. Mita, Henry Xiong, Jordi Rodon
Investigational New Drugs. 2019-02-01 - 1 citationsPhase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancerAmir Mehrvarz Sarshekeh, Henry Q. Xiong, Kenzo Iizuka, Howard S. Hochster, Scott Kopetz
Investigational New Drugs. 2018-06-13
Press Mentions
START Strengthens Dallas-Fort Worth Leadership with Dr. Salwan Al Mutar as Director of Clinical ResearchApril 10th, 2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: